New drug could be cure for common cause of high blood pressure

by | Nov 15, 2026 | Health

New drug could be cure for common cause of high blood pressure

Researchers have identified a medication that may offer lasting treatment for a significant subset of hypertension cases. Baxdrostat, an aldosterone synthase inhibitor, demonstrated the ability to improve blood pressure in patients during a treatment course, with effects remaining stable long after discontinuation of the drug.

The breakthrough emerged from a small study tracking 14 patients who experienced dramatic improvements in hypertension during an initial trial. Participants continued daily doses for six to 12 months, then ceased treatment. Follow-up evaluations conducted up to two years later revealed that blood pressure remained lower than baseline levels. The findings were published in the New England Journal of Medicine.

Primary aldosteronism, which accounts for 5 to 10% of hypertension cases worldwide, stems from small benign tumors on the adrenal glands that trigger overproduction of aldosterone, a hormone that raises blood pressure by prompting the kidneys to retain salt. Current standard treatment involves surgical removal of the affected gland, though this approach does not always fully resolve the condition when other factors contribute to hypertension. The drug received US approval earlier this year for patients whose hypertension remains uncontrolled by conventional medications. Regulatory assessment is underway in the UK, with potential NHS availability next year.

Researchers theorize that baxdrostat may achieve curative effects by triggering destruction of the cells responsible for excessive hormone production. The mechanism appears linked to the generation of reactive oxygen species that selectively eliminate aldosterone-producing cells. This hypothesis draws support from prior mouse research conducted two decades ago, which showed that genetic deletion of the gene required for aldosterone synthesis resulted in loss of hormone-producing cells.

Scientists caution that larger trials are necessary to establish whether the curative effect occurs broadly and persistently across patient populations. If confirmed, the findings could fundamentally reshape diagnostic and treatment protocols for primary aldosteronism, potentially allowing patients to avoid invasive diagnostic procedures and surgical intervention.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI